AveXis (NASDAQ:AVXS) stock price target upped to $50.00, reported earlier today by Jefferies & Co
- Updated: September 19, 2016
Only yesterday AveXis (NASDAQ:AVXS) traded 7.43% higher at $44.39. AVXS’s 50-day moving average is $36.79 and its two hundred day average is $33.25. With the last stock price close up 34.78% from the 200-day moving average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. Volume of trade was was up over the average, with 418,339 shares of AVXS changing hands over the typical 327,330 shares..
In an issued report on Monday September 19 2016 Jefferies & Co raised the target price of AveXis (NASDAQ:AVXS) from $42 to $50 indicating a possible upsideof 0.13%.
Recent Performance Graphic:
Also covering AveXis’s target price, a total of 4 brokerages have released a research note on the stock. The consensus target price is $49.50 with one analyst rating the stock a strong buy, three analysts rating the company a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 firms rating the stock as sell.
AveXis has a 52 week low of $17.40 and a one-year high of $47.76 and has a market capitalization of $0.0.
Brief Synopsis On AveXis (NASDAQ:AVXS)
AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, and which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.